MA41179A - Composés inhibiteurs de parg - Google Patents

Composés inhibiteurs de parg

Info

Publication number
MA41179A
MA41179A MA041179A MA41179A MA41179A MA 41179 A MA41179 A MA 41179A MA 041179 A MA041179 A MA 041179A MA 41179 A MA41179 A MA 41179A MA 41179 A MA41179 A MA 41179A
Authority
MA
Morocco
Prior art keywords
sub
parg
inhibitor compounds
compounds
parg inhibitor
Prior art date
Application number
MA041179A
Other languages
English (en)
Inventor
Niall M Hamilton
James R Hitchin
Colin P Hutton
Allan M Jordan
Alison E Mcgonagle
Kate M Smith
Ian D Waddell
Bohdan Waszkowycz
Original Assignee
Cancer Research Tech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cancer Research Tech Ltd filed Critical Cancer Research Tech Ltd
Publication of MA41179A publication Critical patent/MA41179A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/26—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/84—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D307/85—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Furan Compounds (AREA)

Abstract

La présente invention concerne des composés de la formule i qui fonctionnent en tant qu'inhibiteurs de l'activité enzymatique parg (poly adp-ribose glycohydrolase) : dans ladite formule, r<sub>1a</sub>, r<sub>1b</sub>, r<sub>1c</sub>, r<sub>1d</sub>, r<sub>1e</sub>, w, x<sub>1</sub>, x<sub>2</sub>, x<sub>3</sub>, x<sub>4</sub>, x<sub>5</sub>, x<sub>6</sub>, x<sub>7</sub>, c sont chacun tels que définis dans la description. La présente invention concerne également des procédés de préparation de ces composés, des compositions pharmaceutiques les comprenant et leur utilisation dans le traitement de troubles prolifératifs, tels que le cancer, ainsi que d'autres maladies ou états dans lesquels est impliquée l'activité parg.
MA041179A 2014-12-19 2015-12-16 Composés inhibiteurs de parg MA41179A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB201422771 2014-12-19

Publications (1)

Publication Number Publication Date
MA41179A true MA41179A (fr) 2017-10-24

Family

ID=54937310

Family Applications (1)

Application Number Title Priority Date Filing Date
MA041179A MA41179A (fr) 2014-12-19 2015-12-16 Composés inhibiteurs de parg

Country Status (16)

Country Link
US (4) US10508086B2 (fr)
EP (2) EP3233845B1 (fr)
JP (1) JP6673920B2 (fr)
KR (1) KR102682782B1 (fr)
CN (2) CN112979631B (fr)
AU (1) AU2015365602B2 (fr)
BR (1) BR112017012707B1 (fr)
CA (1) CA2969298C (fr)
ES (1) ES2886471T3 (fr)
IL (1) IL252745B (fr)
MA (1) MA41179A (fr)
MX (1) MX380901B (fr)
RU (1) RU2017125520A (fr)
SG (1) SG11201704843QA (fr)
WO (1) WO2016097749A1 (fr)
ZA (1) ZA201704383B (fr)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA41140A (fr) 2014-12-12 2017-10-17 Cancer Research Tech Ltd Dérivés de 2,4-dioxo-quinazoline-6-sulfonamide en tant qu'inhibiteurs de la parg
MA41179A (fr) 2014-12-19 2017-10-24 Cancer Research Tech Ltd Composés inhibiteurs de parg
EP3947351B1 (fr) 2019-03-29 2026-03-11 Board of Regents, The University of Texas System Inhibiteurs de parg à petites molécules et leurs procédés d'utilisation
CA3147493A1 (fr) * 2019-09-20 2021-03-25 Jr. James Clifford Sutton Derives de sulfonamido d'indole et d'indazole substitues en position 4 en tant qu'inhibiteurs de parg
AU2022359801A1 (en) 2021-10-04 2024-02-01 Forx Therapeutics Ag Parg inhibitory compounds
EP4413000A1 (fr) 2021-10-04 2024-08-14 FoRx Therapeutics AG Dérivés de n,n-diméthyl-4-(7-(n-(1-méthylcyclopropyl)sulfamoyl)-imidazo[1,5-a]pyridin-5-yl)pipérazine-1-carboxamide et dérivés correspondants de pyrazolo[1,5-a]pyridine utilisés en tant qu'inhibiteurs de parg pour le traitement du cancer
WO2024074497A1 (fr) 2022-10-03 2024-04-11 Forx Therapeutics Ag Composé inhibiteur de parg
WO2023064619A1 (fr) 2021-10-17 2023-04-20 University of South Alabama Foundation for Research and Commercialization Traitement contre le cancer
KR20240159579A (ko) * 2022-02-14 2024-11-05 어레이즈 테라퓨틱스 인크. Parg 억제제
WO2023165571A1 (fr) * 2022-03-04 2023-09-07 上海璎黎药业有限公司 Composé contenant une structure cyclique hétéroaromatique à cinq chaînons, composition pharmaceutique et utilisation associées
WO2023175184A1 (fr) 2022-03-17 2023-09-21 Forx Therapeutics Ag Dérivés de 2,4-dioxo-1,4-dihydroquinazoline utilisés comme inhibiteurs de parg pour le traitement du cancer
WO2023175185A1 (fr) 2022-03-17 2023-09-21 Forx Therapeutics Ag Dérivés de 2,4-dioxo-1,4-dihydroquinazoline utilisés en tant qu'inhibiteurs de parg pour le traitement du cancer
AR128846A1 (es) 2022-03-23 2024-06-19 Ideaya Biosciences Inc Compuestos de indazol sustituidos con piperazina como inhibidores de parg
CN114685283B (zh) * 2022-04-06 2024-02-27 南京艾康生物科技有限公司 一种1-(氟甲基)环丙胺盐酸盐的制备方法
WO2023205914A1 (fr) * 2022-04-28 2023-11-02 Danatlas Pharmaceuticals Co., Ltd. Dérivés hétérocycliques tricycliques, compositions et utilisations de ceux-ci
WO2023208092A1 (fr) * 2022-04-28 2023-11-02 Danatlas Pharmaceuticals Co., Ltd. Dérivés hétérocycliques tricycliques, compositions et utilisations de ceux-ci
CN119403803A (zh) 2022-05-17 2025-02-07 858治疗公司 Parg抑制剂
JP2025523576A (ja) * 2022-06-29 2025-07-23 杭州聖域生物医薬科技有限公司 含窒素５，６－縮合化合物、その中間体、調製方法及び用途
CN119522220A (zh) * 2022-07-19 2025-02-25 苏州信诺维医药科技股份有限公司 含硫杂芳环化合物、其药物组合物及其用途
EP4311829A1 (fr) 2022-07-28 2024-01-31 Nodus Oncology Limited Dérivés d'hétéroaryl sulfonamide bicyclique substitués pour le traitement du cancer
AR130748A1 (es) * 2022-10-13 2025-01-15 Hanmi Pharmaceutical Co Ltd Compuesto heterobicíclico para inhibir la interacción yap-tead y composición farmacéutica que lo comprende
WO2024120519A1 (fr) * 2022-12-09 2024-06-13 捷思英达控股有限公司 Inhibiteur de tead, procédé de préparation associé et utilisation médicale de celui-ci
WO2024173234A1 (fr) * 2023-02-13 2024-08-22 Arase Therapeutics Inc. Inhibiteurs de parg
WO2024209035A1 (fr) 2023-04-05 2024-10-10 Forx Therapeutics Ag Composés inhibiteurs de parg
AU2024262278A1 (en) * 2023-04-27 2025-12-18 Danatlas Pharmaceuticals Co., Ltd. Tricyclic heterocyclic derivatives, compositions and uses thereof
EP4716532A2 (fr) * 2023-05-23 2026-04-01 Quantx Biosciences US, Inc. Composés hétéroaryles bicycliques
WO2024254990A1 (fr) * 2023-06-16 2024-12-19 上海璎黎药业有限公司 Composé ayant une structure cyclique hétéroaromatique, composition pharmaceutique associée et son utilisation
WO2025035108A2 (fr) * 2023-08-10 2025-02-13 Arase Therapeutics Inc. Inhibiteurs de parg
WO2025046148A1 (fr) 2023-09-01 2025-03-06 Forx Therapeutics Ag Nouveaux inhibiteurs de parg
WO2025070690A1 (fr) 2023-09-29 2025-04-03 第一三共株式会社 Dérivé de 3-phénylpropylamine
CN121889393A (zh) 2023-10-03 2026-04-17 福克斯治疗股份公司 Parg抑制化合物
WO2025093755A1 (fr) 2023-11-01 2025-05-08 Forx Therapeutics Ag Nouveaux inhibiteurs de parg
WO2025098445A1 (fr) * 2023-11-07 2025-05-15 南京同诺康医药科技有限公司 Inhibiteur de parg, son procédé de préparation et son utilisation
WO2025108225A1 (fr) * 2023-11-20 2025-05-30 上海复星医药（集团）股份有限公司 Dérivé tricyclique contenant de l'azote en tant qu'inhibiteur de parg
WO2025133396A1 (fr) 2023-12-22 2025-06-26 Forx Therapeutics Ag Nouveaux inhibiteurs de parg bicyclo hétéroaryles
WO2025229549A1 (fr) * 2024-04-30 2025-11-06 Satyarx Pharma Innovations Pvt Ltd Nouveaux composés hétérocycliques utilisés en tant qu'inhibiteurs de parg
WO2026022150A1 (fr) 2024-07-22 2026-01-29 Forx Therapeutics Ag Composés inhibiteurs de parg
WO2026033475A1 (fr) * 2024-08-09 2026-02-12 Avelos Therapeutics Inc. Dérivés de composés aryle ou hétéroaryle substitués et leur utilisation pharmaceutique
WO2026040953A1 (fr) * 2024-08-19 2026-02-26 上海和誉生物医药科技有限公司 Inhibiteur de parg polycyclique et ses utilisations
WO2026062066A1 (fr) 2024-09-17 2026-03-26 Forx Therapeutics Ag Composés induisant une dégradation de parg

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1157858A (fr) 1979-12-03 1983-11-29 Ikuo Ueda Derives de quinazoline
DE4407047A1 (de) 1994-03-03 1995-09-07 Merck Patent Gmbh Acetamide
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
WO1997030035A1 (fr) 1996-02-13 1997-08-21 Zeneca Limited Derives de la quinazoline utilises comme inhibiteurs du vegf
ES2169355T3 (es) 1996-03-05 2002-07-01 Astrazeneca Ab Derivados de 4-anilinoquinazolina.
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
EP1131856A1 (fr) 1998-11-12 2001-09-12 BAE Systems Electronics Ltd. Etalement de faisceaux electromagnetiques
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
BRPI0017548B8 (pt) 1999-02-10 2023-05-02 Astrazeneca Ab Composto
DE19927415A1 (de) * 1999-06-16 2000-12-21 Bayer Ag Indolinylharnstoffderivate
PE20010306A1 (es) * 1999-07-02 2001-03-29 Agouron Pharma Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa
US6566372B1 (en) 1999-08-27 2003-05-20 Ligand Pharmaceuticals Incorporated Bicyclic androgen and progesterone receptor modulator compounds and methods
IL152682A0 (en) 2000-05-31 2003-06-24 Astrazeneca Ab Indole derivatives with vascular damaging activity
UA73993C2 (uk) 2000-06-06 2005-10-17 Астразенека Аб Хіназолінові похідні для лікування пухлин та фармацевтична композиція
BR0112224A (pt) 2000-07-07 2003-06-10 Angiogene Pharm Ltd Composto, composição farmacêutica, uso de um composto ou de um sal, solvato ou pró-droga farmaceuticamente aceitável do mesmo, e, processo para preparar um composto
HUP0301742A3 (en) 2000-07-07 2005-08-29 Angiogene Pharm Ltd Colchinol derivatives as angiogenesis inhibitors, process for producing them, pharmaceutical compositions containing them and their use
TW200303304A (en) 2002-02-18 2003-09-01 Astrazeneca Ab Chemical compounds
US7009052B2 (en) 2003-03-20 2006-03-07 Warner Lambert Company Llc Sulfonamide derivatives
GB0322722D0 (en) 2003-09-27 2003-10-29 Glaxo Group Ltd Compounds
TWI332003B (en) 2004-01-30 2010-10-21 Lilly Co Eli Kinase inhibitors
US20070049593A1 (en) * 2004-02-24 2007-03-01 Japan Tobacco Inc. Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor
PT1719773E (pt) 2004-02-24 2009-06-03 Japan Tobacco Inc Compostos heterotetracíclicos fundidos e a sua utilização como inibidores da polimerase do hcv
RU2417225C2 (ru) 2004-03-25 2011-04-27 Мемори Фармасьютиклз Корпорейшн Индазолы, бензотиазолы, бензоизотиазолы, бензизоксазолы и их получение и применение
WO2007014226A2 (fr) * 2005-07-26 2007-02-01 The Board Of Trustees Of The University Of Illinois Composes pour le traitement de neurodegenerescence et d'accident cerebro-vasculaire
CN101374808B (zh) * 2006-01-24 2011-05-25 伊莱利利公司 孕酮受体的吲哚磺酰胺调节剂
CA2645583A1 (fr) 2006-03-20 2007-09-27 F. Hoffman-La Roche Ag Procedes d'inhibition des proteines kinase btk et syk
US20100298289A1 (en) 2007-10-09 2010-11-25 Ucb Pharma, S.A. Heterobicyclic compounds as histamine h4-receptor antagonists
EP2211854A4 (fr) 2007-10-19 2011-01-12 Bipar Sciences Inc Procédés et compositions pour le traitement du cancer au moyen d'inhibiteurs de parp de type benzopyrone
JPWO2010007944A1 (ja) * 2008-07-17 2012-01-05 旭化成ファーマ株式会社 含窒素二環性複素環化合物
CN101429191B (zh) 2008-11-03 2012-05-23 中国药科大学 取代的四氢异喹啉衍生物的用途
EA201290642A1 (ru) 2010-01-13 2013-05-30 ГЛЭКСОСМИТКЛАЙН ЭлЭлСи Соединения и способы
WO2011140325A1 (fr) * 2010-05-07 2011-11-10 Glaxosmithkline Llc Indazoles
ES2552977T3 (es) 2010-05-07 2015-12-03 Glaxosmithkline Intellectual Property Development Limited Amino-quinolinas como inhibidores de quinasa
US8697739B2 (en) 2010-07-29 2014-04-15 Novartis Ag Bicyclic acetyl-CoA carboxylase inhibitors and uses thereof
JP2013537210A (ja) 2010-09-16 2013-09-30 ノバルティス アーゲー １７α−ヒドロキシラーゼ／Ｃ１７，２０−リアーゼ阻害剤
TW201307292A (zh) 2010-12-17 2013-02-16 Hoffmann La Roche 經取代之６，６－稠合含氮雜環化合物及其用途
EP2471363A1 (fr) 2010-12-30 2012-07-04 Bayer CropScience AG Utilisation d'acides aryl-, hétéroaryl- et benzylsulfonaminés, d'esters d'acide aminé, d'amides d'acide aminé et carbonitrile ou leurs sels pour l'augmentation de la tolérance au stress dans des plantes
WO2012160464A1 (fr) 2011-05-26 2012-11-29 Daiichi Sankyo Company, Limited Composés hétérocycliques en tant qu'inhibiteurs de protéine kinase
WO2013027168A1 (fr) 2011-08-22 2013-02-28 Pfizer Inc. Nouveaux composés hétérocycliques utilisés en tant qu'inhibiteurs de bromodomaine
WO2013067300A1 (fr) 2011-11-04 2013-05-10 Glaxosmithkline Intellectual Property (No. 2) Limited Méthode de traitement
WO2014026327A1 (fr) 2012-08-15 2014-02-20 Merck Sharp & Dohme Corp. Composés d'acide benzoïque à substitution 4-hétéroaryle en tant qu'inhibiteurs de rorgammat et leurs utilisations
CA2896554C (fr) 2012-12-27 2019-11-05 Drexel University Nouveaux agents antiviraux contre une infection par le vhb
CA2939021C (fr) 2014-02-11 2022-07-12 Bayer Pharma Aktiengesellschaft Benzimidazol-2-amines utilisees en tant qu'inhibiteurs de midh1
US10233195B2 (en) 2014-04-02 2019-03-19 Intermune, Inc. Anti-fibrotic pyridinones
MA41140A (fr) 2014-12-12 2017-10-17 Cancer Research Tech Ltd Dérivés de 2,4-dioxo-quinazoline-6-sulfonamide en tant qu'inhibiteurs de la parg
MA41179A (fr) 2014-12-19 2017-10-24 Cancer Research Tech Ltd Composés inhibiteurs de parg
KR20190078646A (ko) 2016-11-18 2019-07-04 머크 샤프 앤드 돔 코포레이션 디아실글리세리드 o-아실트랜스퍼라제 2의 억제제로서 유용한 인다졸 유도체
EP3947351B1 (fr) 2019-03-29 2026-03-11 Board of Regents, The University of Texas System Inhibiteurs de parg à petites molécules et leurs procédés d'utilisation
CA3147493A1 (fr) 2019-09-20 2021-03-25 Jr. James Clifford Sutton Derives de sulfonamido d'indole et d'indazole substitues en position 4 en tant qu'inhibiteurs de parg
AU2022359801A1 (en) 2021-10-04 2024-02-01 Forx Therapeutics Ag Parg inhibitory compounds
AR128846A1 (es) 2022-03-23 2024-06-19 Ideaya Biosciences Inc Compuestos de indazol sustituidos con piperazina como inhibidores de parg

Also Published As

Publication number Publication date
WO2016097749A1 (fr) 2016-06-23
KR102682782B1 (ko) 2024-07-12
RU2017125520A (ru) 2019-01-21
JP2017538750A (ja) 2017-12-28
ZA201704383B (en) 2022-03-30
CN107295799A (zh) 2017-10-24
US10995073B2 (en) 2021-05-04
RU2017125520A3 (fr) 2019-06-06
EP3233845A1 (fr) 2017-10-25
CN112979631B (zh) 2024-09-20
SG11201704843QA (en) 2017-07-28
US10508086B2 (en) 2019-12-17
US20250223266A1 (en) 2025-07-10
IL252745A0 (en) 2017-08-31
CA2969298C (fr) 2023-10-17
US12129236B2 (en) 2024-10-29
ES2886471T3 (es) 2021-12-20
EP3233845B1 (fr) 2021-07-21
BR112017012707B1 (pt) 2023-10-24
NZ732394A (en) 2024-01-26
CN107295799B (zh) 2021-03-16
EP3907224A1 (fr) 2021-11-10
JP6673920B2 (ja) 2020-03-25
MX2017007976A (es) 2018-03-26
CA2969298A1 (fr) 2016-06-23
US20210380539A1 (en) 2021-12-09
US20180194738A1 (en) 2018-07-12
KR20170095370A (ko) 2017-08-22
MX380901B (es) 2025-03-12
AU2015365602A1 (en) 2017-06-29
CN112979631A (zh) 2021-06-18
IL252745B (en) 2020-03-31
AU2015365602B2 (en) 2020-02-27
HK1245253A1 (zh) 2018-08-24
US20200165208A1 (en) 2020-05-28
BR112017012707A2 (pt) 2018-01-02

Similar Documents

Publication Publication Date Title
JOP20240084A1 (ar) مركبات الكينولين كمثبطات لـ kras
MX380901B (es) Compuestos inhibidores de parg.
MA64509B1 (fr) Composés hétérocycliques utilisés comme immunomodulateurs
MA64121B1 (fr) Composés hétérocycliques utilisés comme immunomodulateurs
MX2023005636A (es) Inhibidores de bcl6 derivados de bencimidazolona.
JOP20170126A1 (ar) مركبات 3-أكسو-2، 6-ثنائي فنيل-2، 3-ثنائي هيدروبيريدازين-4-كربوكساميد
MA47043A1 (fr) Composés indole carboxamides utiles comme inhibiteurs de kinase
MA38380A1 (fr) Inhibiteurs quinazoline de l&#39;activation des formes mutantes du récepteur de croissance épidermique (egfr)
MA53399B1 (fr) Pyrazoles substitués en tant qu`inhibiteurs de la kallicréine plasmatique humaine
MA38483A1 (fr) Inhibiteurs de l&#39;ido
MX383856B (es) Compuestos y composiciones para inhibir la actividad de shp2.
MA43979B1 (fr) Dérivés de 1h-indazole-3-carboxamide et composés similaires en tant qu&#39;inhibiteurs du facteur d pour le traitement de maladies characterisés par une activité aberrante du système complémentaire, comme p.E. Troubles immunologiques
EP4371562A3 (fr) Dérivés de la 2-quinolone en tant qu&#39;inhibiteurs du récepteur bcl6
MA34969B1 (fr) Composes et compositions en tant qu inibiteurs de trk
TN2014000420A1 (fr) Derives d&#39;indole et d&#39;indazole qui activent la mpk
MA40955B1 (fr) 2-amino-6-(difluorométhyl)-5,5-difluoro-6-phényl-3,4,5,6-tétrahydropyridines comme inhibiteurs de bace1
MA46229B1 (fr) Composés d&#39;hétéroaryle carboxamide en tant qu&#39;inhibiteurs de ripk2
MA44948A1 (fr) Inhibiteurs de bace 1
MA43052B1 (fr) Inhibiteurs de la kallicréine plasmatique humaine
MA37691B1 (fr) 5-amino[1,4]thiazines comme inhibiteurs de bace1
MA37763A1 (fr) Difluoro-hexahydro-cyclopentaoxazinyles et difluoro-hexahydro-benzooxazinyles en tant qu&#39;inhibiteurs de bace1
MA39253B1 (fr) Composés hétéroaryle bicycliques substitués utilisés comme agonistes de rxr
PH12022552775A1 (en) Tetrahydroisoquinoline compounds as nrf2 activators
MA43250B1 (fr) Composés d&#39;oxadiazaspiro pour le traitement de l&#39;abus et la dépendance aux drogues
MA43158B1 (fr) Composés oxa-diazadispiro possédant une activité contre la douleur